Precision Performance Status Compared With ECOG Performance Status

Precision Performance Status Compared With ECOG Performance Status- A Pilot Cross Sectional Observational Study

This study compares consumer movement trackers to the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) in monitoring cancer patient movement. The ECOG PS emphasizes a patient's ambulatory status (ability to walk around), and scores patients on a scale of 0-5: 0 (no restrictions), 1 (ambulatory), 2 (< 50% of hours spent in bed, unable to carry out work activities), 3 (> 50% of hours spent in bed, limited in self care), 4 (bedbound and gravely disabled) and 5 (deceased). Accurate assessment of a patient's PS is paramount in informing therapeutic decision-making, whether it be to predict response and tolerability to treatment or determine eligibility for clinical trials. However, the ECOG PS scale is observational, and therefore limited in its precision. Information gained in this study may help researchers learn if there is a better way to assess patient movement with computerized analysis tools using movement trackers.

Study Overview

• Status: Terminated
• Conditions: Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm
• Intervention / Treatment: Other: Functional Assessment; Behavioral: Timed Get Up and Go Test

Detailed Description

PRIMARY OBJECTIVE:

I. To determine the correlation between patient acceleration of the spine base/non-pivoting leg captured with in-office movement trackers, and physician/patient assessed Eastern Cooperative Oncology Group (ECOG) performance status (PS) using a Microsoft Kinect movement tracker.

SECONDARY OBJECTIVES:

I. To determine the correlation between clinician/patient assessed ECOG PS and Kinect assessed ECOG PS score.

II. To determine the range of measured patient acceleration measurements for each ECOG score between 0 and 3.

OUTLINE: This is an observational study.

Patients undergo "Get Up and Go" assessment as well as a chair-to-table assessment during the clinic visit on study.

• Study Type: Observational
• Enrollment (Actual): 41

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90033
      • USC / Norris Comprehensive Cancer Center
    • Los Angeles, California, United States, 90033
      • Los Angeles General Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Cancer patients with appointments at University of Southern California (USC)/Norris Cancer Center

Description

Inclusion Criteria:

• A diagnosis of cancer
• Age >= 18 years
• Ability to understand and the willingness to sign a written informed consent
• Able to ambulate without an assistive device

Exclusion Criteria:

• Missing lower limbs
• Known movement disorder such as Parkinson's disease, choreoathetoid movement disorders, essential tremor if that movement disorder is of sufficient severity to require drug therapy

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Observational ("Get Up and Go" and chair-to-table assessments); Patients undergo "Get Up and Go" assessment as well as a chair-to-table assessment during the clinic visit on study.	Other: Functional Assessment; Undergo chair-to-table assessment; Behavioral: Timed Get Up and Go Test; Undergo "Get Up and Go" assessment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Median acceleration at the Spine Base and non-pivoting leg	The Kinect device will record the participant performing the chair to examination table activity and the Get up and Go activity. This recording will quantify spine and non-pivoting leg mean acceleration during movement onto an examination table and the Get up and Go time. These values will be assessed for a linear or monotonic relationship with Eastern Cooperative Oncology Group (ECOG) scores. If a linear relationship is exhibited the primary objective will be evaluated via a Pearson correlation coefficient. However, the supposition is the data will more likely reflect a monotonic relationship. In this event the primary objective will be evaluated via a Kendall Rank Tau-b correlation coefficient.	Day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Video recording assessed ECOG Performance Status (PS) measurement	The relationship between ECOG PS determined subjectively in clinic and ECOG PS determined by reviewing the Kinect recording will be assessed for a linear or monotonic relationship. However, the supposition is a linear relationship is more likely. A Pearson or Kendall Rank correlation will be utilized accordingly to evaluate a correlation.	Baseline

Collaborators and Investigators

• Sponsor: University of Southern California
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Jorge J Nieva, MD, University of Southern California

Publications and helpful links

General Publications

• Wang C, Prasad A, Qi E, Pai J, Law J, Chennapan K, Jirka G, Kuhn P, Tale M, Nocera L, Nieva J. Augmenting Performance Status: A Preliminary Study of Objective Kinematic Assessment Using Motion Capture. Oncol Ther. 2026 May 7. doi: 10.1007/s40487-026-00434-x. Online ahead of print.

Study record dates

Study Major Dates

• Study Start (Actual): November 22, 2022
• Primary Completion (Actual): May 28, 2024
• Study Completion (Actual): May 22, 2026

Study Registration Dates

• First Submitted: July 10, 2025
• First Submitted That Met QC Criteria: July 21, 2025
• First Posted (Actual): July 24, 2025

Study Record Updates

• Last Update Posted (Actual): May 28, 2026
• Last Update Submitted That Met QC Criteria: May 26, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: 0S-22-6 (Other Identifier: USC / Norris Comprehensive Cancer Center); P30CA014089 (U.S. NIH Grant/Contract); NCI-2022-09079 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No